McKesson (NYSE:MCK) Updates FY 2027 Earnings Guidance

McKesson (NYSE:MCK) updated its FY 2027 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 43.800-44.600 for the period, compared to the consensus estimate of 44.130. The company issued revenue guidance of -.

Analyst Ratings Changes

MCK has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $875.00 price objective on shares of McKesson in a research note on Friday. Mizuho upped their target price on shares of McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research note on Thursday, February 5th. Leerink Partners reaffirmed an “outperform” rating and set a $1,085.00 price target on shares of McKesson in a research note on Thursday, March 5th. Wall Street Zen upgraded shares of McKesson from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Wells Fargo & Company upped their price objective on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research report on Thursday, February 5th. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and a consensus target price of $970.73.

McKesson Stock Down 2.6%

Shares of MCK opened at $734.93 on Friday. The firm has a market cap of $90.02 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 1.09 and a beta of 0.35. The business’s 50 day moving average is $883.74 and its two-hundred day moving average is $859.93. McKesson has a 52-week low of $637.00 and a 52-week high of $999.00.

McKesson (NYSE:MCK) last released its quarterly earnings results on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, topping analysts’ consensus estimates of $11.56 by $0.13. The business had revenue of $96.30 billion during the quarter, compared to the consensus estimate of $101.35 billion. McKesson had a net margin of 1.18% and a negative return on equity of 378.75%. The business’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter last year, the company earned $10.12 earnings per share. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, equities analysts expect that McKesson will post 44.24 earnings per share for the current fiscal year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson’s payout ratio is presently 8.53%.

Insider Activity

In related news, Director Maria Martinez sold 349 shares of McKesson stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $939.87, for a total value of $328,014.63. Following the completion of the transaction, the director directly owned 301 shares in the company, valued at approximately $282,900.87. This trade represents a 53.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Leann B. Smith sold 190 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the sale, the executive vice president directly owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. This represents a 5.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 3,264 shares of company stock worth $3,205,315. 0.08% of the stock is currently owned by corporate insiders.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat quarterly adjusted EPS estimates, reporting $11.69 per share versus $11.56 expected, and cited strength in oncology, specialty distribution, and biopharma services. Reuters article
• Positive Sentiment: The company guided fiscal 2027 EPS to $43.80-$44.60, which is roughly in line with expectations and suggests continued earnings growth. McKesson also reaffirmed its long-term financial targets. Yahoo Finance article
• Positive Sentiment: JPMorgan lowered its price target to $1,015 from $1,107 but kept an overweight rating, implying meaningful upside from the current share price. Benzinga article
• Positive Sentiment: William Blair reiterated a Buy rating, saying McKesson’s durable earnings power and fiscal 2027 growth outlook outweigh near-term revenue softness. TipRanks article
• Neutral Sentiment: McKesson advanced plans for its $13 billion medical-surgical spinoff/separation, a strategic move that could unlock value over time but also adds execution risk. MSN article
• Negative Sentiment: Revenue came in below Wall Street forecasts at $96.3 billion versus $101.35 billion expected, reinforcing concerns about softer sales momentum despite improved margins. Yahoo Finance article
• Negative Sentiment: The stock has been trading lower as investors focus on the revenue shortfall and near-term softness in the medical-surgical business, even with strong earnings and guidance. Zacks article

Institutional Investors Weigh In On McKesson

A number of institutional investors have recently made changes to their positions in MCK. University of Texas Texas AM Investment Management Co. bought a new position in McKesson during the fourth quarter worth $25,000. Swiss RE Ltd. bought a new stake in McKesson during the fourth quarter valued at $26,000. State of Wyoming acquired a new stake in shares of McKesson during the second quarter worth $29,000. Birchwood Financial Partners Inc. bought a new position in shares of McKesson in the 4th quarter worth about $33,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of McKesson in the 4th quarter worth about $39,000. 85.07% of the stock is currently owned by institutional investors.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.